Recent developments in potential anxiolytic agents targeting GABA A/BzR complex or the translocator protein (18kDa) (TSPO)

Current Topics in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 360-370

  Nothdurfter, Caroline ^a,b   Rupprecht, Rainer ^a,b   Rammes, Gerhard ^b,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anxiety disorder; Anxiolytic; Benzodiazepines; GABA A; Neuroactive steroids; Receptor; Subtype specific; TSPO

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; ALFAXALONE; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE; EMAPUNIL; ETIFOXINE; FINASTERIDE; FLAVONOID; GABAPENTIN; GABOXADOL; GANAXOLONE; LORAZEPAM; NSD 721; OCINAPLON; PENTETRAZOLE; PLACEBO; PLANT MEDICINAL PRODUCT; PREGABALIN; SILEXAN; TIAGABINE; TPA 023; UNCLASSIFIED DRUG; VALERENIC ACID; VIGABATRIN;

ABSENCE OF SIDE EFFECTS; ADJUSTMENT DISORDER; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; AROMATHERAPY; BINDING AFFINITY; COMPLEX PARTIAL SEIZURE; DIZZINESS; DRUG BINDING SITE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INFANTILE SPASM; JAUNDICE; LIVER TOXICITY; MEMORY DISORDER; MITOCHONDRIAL MEMBRANE; MOTOR COORDINATION; MUSCLE RELAXATION; NAUSEA; NEUROMODULATION; NONHUMAN; PANIC; POSTTRAUMATIC STRESS DISORDER; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; STEROIDOGENESIS; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BINDING SITES; BRAIN; GABA-A RECEPTOR AGONISTS; HUMANS; LIGANDS; NEUROTRANSMITTER AGENTS; PLANT EXTRACTS; PROTEIN BINDING; PROTEIN SUBUNITS; RECEPTORS, GABA; RECEPTORS, GABA-A; SEROTONIN UPTAKE INHIBITORS;

EID: 84856477354     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799078748     Document Type: Review

References (117)

1. Kessler, R. C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K. R.; Walters, E. E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62, 593-602.
2. Wang, P. S.; Berglund, P.; Olfson, M.; Pincus, H. A.; Wells, K. B.; Kessler, R. C. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62, 603-613.
3. Baldwin, D. S., Anderson, I. M.; Nutt, D. J.; Bandelow, B.; Bond, A.; Davidson, J. R.; den Boer, J. A.; Fineberg, N. A.; Knapp, M.; Scott, J.; Wittchen, H. U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol., 2005, 19, 567-596.
4. Uusi-Oukari, M.; Korpi, E. R. Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol. Rev., 2010, 62, 97-135.
5. Bandelow, B.; Zohar, J.; Hollander, E.; Kasper, S.; Moller, H. J.; Allgulander, C.; Ayuso-Gutierrez, J.; Baldwin, D. S.; Buenvicius, R.;Cassano, G.; Fineberg, N.; Gabriels, L.; Hindmarch, I.; Kaiya, H.; Klein, D. F.; Lader, M.; Lecrubier, Y.; Lepine, J. P.;Liebowitz, M. R.; Lopez-Ibor, J. J.; Marazziti, D.; Miguel, E. C.; Oh, K. S.; Preter, M.; Rupprecht, R.; Sato, M.; Starcevic, V.; Stein, D. J.; van Ameringen, M.; Vega, J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry, 2008, 9, 248-312.
6. Sheehan, D. V. The management of panic disorder. J. Clin. Psychiatry, 2002, 63 (Suppl 14), 17-21.
7. Kalueff, A. V.; Nutt, D. J. Role of GABA in anxiety and depression. Depress Anxiety, 2007, 24, 495-517.
8. Sieghart, W.; Fuchs, K.; Tretter, V.; Ebert, V.; Jechlinger, M.; Hoger, H.; Adamiker, D. Structure and subunit composition of GABA(A) receptors. Neurochem. Int., 1999, 34, 379-385.
9. A receptor subtype functions. Curr. Opin. Pharmacol., 2006, 6, 18-23.
10. Korpi, E. R.; Sinkkonen, S. T. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol. Ther., 2006, 109, 12-32.
11. Mohler, H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res., 2006, 326, 505-516.
12. Rupprecht, R.; Holsboer, F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci., 1999, 22, 410-416.
13. Rupprecht, R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinol., 2003, 28, 139-168.
14. Ströhle, A.; Romeo, E.; di Michele, F.; Pasini, A.; Hermann, B.; Gajewsky, G.; Holsboer, F.; Rupprecht, R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch. Gen. Psychiatry, 2003, 60, 161-168.
15. Krueger, K. E.; Papadopoulos, V. Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells. J. Biol. Chem., 1990, 265, 15015-15022.
16. Krueger, K. E.; Papadopoulos, V. Mitochondrial benzodiazepine receptors and the regulation of steroid biosynthesis. Annu. Rev. Pharmacol. Toxicol., 1992, 32, 211-237.
17. Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapere, J. J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M. R.; Gavish, M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci., 2006, 27, 402-409.
18. Nakamura, K.; Fukunishi, I.; Nakamoto, Y.; Iwahashi, K.; Yoshii, M. Peripheral-type benzodiazepine receptors on platelets are correlated with the degrees of anxiety in normal human subjects. Psychopharmcol., 2002, 162, 301-303.
19. Nudmamud, S.; Siripurkpong, P.; Chindaduangratana, C.; Harnyuttanakorn, P.; Lotrakul, P.; Laarbboonsarp, W.; Srikiatkhachorn, A.; Kotchabhakdi, N.; Casalotti, S. Stress, anxiety and peripheral benzodiazepine receptor mRNA levels in human lymphocytes. Life Sci., 2000, 67, 2221-2231.
20. Rocca, P.; Beoni, A. M.; Eva, C.; Ferrero, P.; Zanalda, E.; Ravizza, P. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol. Psychiatry., 1998, 43, 767-773.
21. Veenman, L., Gavish, M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther., 2006, 110, 503-524.
22. Avital, A.; Richter-Levin, G.; Leschiner, S.; Spanier, I.; Veenman, L.; Weizman, A.; Gavish, M. Acute and repeated swim stress effects on peripheral benzodiazepine receptors in the rat hippocampus, adrenal, and kidney. Neuropsychopharmacology, 2001, 25, 669-678.
23. Da Settimo, F.; Simorini, F.; Taliani, S.; La Motta, C.; Marini, A. M.; Salerno, S.; Bellandi, M.; Novellino, E.; Greco, G.; Cosimelli, B.; Da Pozzo, E.; Costa, B.; Simola, N.; Morelli, M.; Martini, C. Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J. Med. Chem., 2008, 51, 5798-5806.
24. Taliani, S.; Da Settimo, F.; Da Pozzo, E.; Chelli, B.; Martini, C. Translocator protein ligands as promising therapeutic tools for anxiety disorders. Curr. Med. Chem., 2009, 16, 3359-3380.
25. Taliani, S.; Pugliesi, I.; Da Settimo, F. Structural Requirements to Obtain Highly Potent and Selective 18 kDa Translocator Protein (TSPO) Ligands. Curr. Top. Med. Chem., 2011 11(7), 860-886.
26. Weizman, A.; Fares, F.; Pick, C. G.; Yanai, J.; Gavish, M. Chronic phenobarbital administration affects GABA and benzodiazepine receptors in the brain and periphery. Eur. J. Pharmacol., 1989, 169,235-240.
27. Weizman, R.; Gavish, M. Chronic diazepam treatment induces an increase in peripheral benzodiazepine binding sites. Clin. Neuropharmacol., 1989, 12, 346-351.
28. A receptors expressed in Xenopus oocytes by perfume and phytoncid. Biosci. Biotechnol. Biochem., 1999, 63, 743-748.
29. Woelk, H.; Schlafke, S. A multi-center, double-blind, randomized study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine, 2010, 17, 94-99.
30. Kasper, S., Gastpar, M., Muller, W. E.; Volz, H. P.; Moller, H. J.; Dienel, A.; Schlafke, S. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. Int. Clin. Psychopharmacol., 2010, 25, 277-287.
31. Houghton, P. J. The scientific basis for the reputed activity of Valerian. J. Pharm. Pharmacol., 1999, 51, 505-512.
32. Khom, S.; Baburin, I.; Timin, E.; Hohaus, A.; Trauner, G.; Kopp, B.; Hering, S. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology, 2007, 53, 178-187.
33. Benke, D.; Barberis, A.; Kopp, S.; Altmann, K. H.; Schubiger, M.; Vogt, K. E.; Rudolph, U.; Mohler, H. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology, 2009, 56, 174-181.
34. A receptor ligands - in vitro and in vivo characterization. Br. J. Pharmacol., 2010, 161, 65-78.
35. Ren, L.; Wang, F.; Xu, Z.; Chan, W. M.; Zhao, C.; Xue, H. GABA(A) receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem. Pharmacol., 2010, 79, 1337-1344.
36. Wang, F.; Xu, Z.; Ren, L.; Tsang, S. Y.; Xue, H. GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Neuropharmacology, 2008, 55, 1231-1237.
37. Gulinello, M.; Gong, Q. H.; Smith, S. S. Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A) receptors. Neuroreport, 2003, 14, 43-46.
38. Hoehn-Saric, R. Effects of THIP on chronic anxiety. Psychopharmacology (Berl), 1983, 80, 338-341.
39. Lippert, B.; Metcalf, B. W.; Jung, M. J.; Casara, P. 4-amino-hex-5- enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur. J. Biochem., 1977, 74, 441-445.
40. Tolman, J. A.; Faulkner, M. A. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin. Pharmacother., 2009, 10, 3077-3089.
41. Zwanzger, P.; Baghai, T. C.; Schuele, C.; Strohle, A.; Padberg, F.; Kathmann, N.; Schwarz, M.; Moller, H. J.; Rupprecht, R. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology, 2001, 25, 699-703.
42. A receptors as targets for novel anxiolytic drugs. World J. Biol. Psychiatry, 2006, 7, 231-237.
43. Nielsen, E. B.; Suzdak, P. D.; Andersen, K. E.; Knutsen, L. J.; Sonnewald, U.; Braestrup, C. Characterization of tiagabine (NO- 328), a new potent and selective GABA uptake inhibitor. Eur. J. Pharmacol., 1991, 196, 257-266.
44. Zwanzger, P.; Eser, D.; Padberg, F.; Baghai, T. C.; Schule, C., Rotzer, F.; Ella, R.; Moller, H. J.; Rupprecht, R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety, 2003, 18, 140-143.
45. Pollack, M. H.; Roy-Byrne, P. P.; van Ameringen, M.; Snyder, H.; Brown, C.; Ondrasik, J., Rickels, K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry, 2005, 66, 1401-1408.
46. Connor, K. M.; Davidson, J. R.; Weisler, R. H.; Zhang, W.; Abraham, K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl), 2006, 184, 21-25.
47. Dunlop, B. W.; Papp, L.; Garlow, S. J.; Weiss, P. S.; Knight, B. T.; Ninan, P. T. Tiagabine for social anxiety disorder. Hum. Psychopharmacol., 2007, 22, 241-244.
48. Pollack, M. H.; Tiller, J.; Xie, F., Trivedi, M. H. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J. Clin. Psychopharmacol., 2008, 28, 308-316.
49. Sheehan, D. V.; Sheehan, K. H.; Raj, B. A.; Janavs, J. An openlabel study of tiagabine in panic disorder. Psychopharmacol. Bull., 2007, 40, 32-40.
50. Zwanzger, P.; Eser, D.; Nothdurfter, C.; Baghai, T. C.; Moller, H. J.; Padberg, F.; Rupprecht, R. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry, 2009, 42, 266-269.
51. Baldwin, D. S.; Polkinghorn, C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int. J. Neuropsychopharmacol., 2005, 8, 293-302.
52. Tzellos, T. G.; Papazisis, G.; Toulis, K. A.; Sardeli, C.; Kouvelas, D. A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia, 2010, 14, 71-75.
53. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J. A.; Fritschy, J. M.; Rulicke, T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science, 2000, 290, 131-134.
54. A receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev., 2003, 9, 3-20.
55. A receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-ylcarbonyl)- 2,9-dihydro-1H-pyridol[3, 4-b]indol-1-one]. J. Pharmacol. Exp. Ther., 2005, 313, 1118-1125.
56. de Haas, S. L.; Franson, K. L.; Schmitt, J. A.; Cohen, A. F.; Fau, J. B.; Dubruc, C.; van Gerven, J. M. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J. Psychopharmacol., 2009, 23, 625-632.
57. A receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther., 2006, 316, 410-422
58. de Haas, S. L.; de Visser, S. J.; van der Post, J. P.; de Smet, M.; Schoemaker, R. C.; Rijnbeek, B.; Cohen, A. F.; Vega, J. M.; Agrawal, N. G.; Goel, T. V.; Simpson, R. C.; Pearson, L. K.; Li, S.; Hesney, M.; Murphy, M. G.; van Gerven, J. M. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J. Psychopharmacol., 2007, 21, 374-383.
59. Atack, J. R. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv. Pharmacol., 2009, 57, 137-185.
60. Berezhnoy, D.; Gravielle, M. C.; Downing, S.; Kostakis, E.; Basile, A. S.; Skolnick, P.; Gibbs, T. T.; Farb, D. H. Pharmacological Properties of DOV 315,090, an ocinaplon metabolite. BMC Pharmacol., 2008, 8, 11.
61. Lippa, A.; Czobor, P.; Stark, J.; Beer, B., Kostakis, E., Gravielle, M., Bandyopadhyay, S., Russek, S. J.; Gibbs, T. T., Farb, D. H.; Skolnick, P. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc. Natl. Acad. Sci. USA, 2005, 102, 7380-7385.
62. Czobor, P.; Skolnick, P.; Beer, B.; Lippa, A. A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder. CNS Neurosci. Ther., 2010, 16, 63-75.
63. Galiegue, S.; Tinel, N.; Casellas, P. The peripheral benzodiazepine receptor: a promising therapeutic drug target. Curr. Med. Chem., 2003, 10, 1563-1572.
64. Gavish, M.; Bachman, I.; Shoukrun, R.; Katz, Y.; Veenman, L.; Weisinger, G.; Weizman, A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev., 1999, 51, 629-650.
65. James, M. L.; Selleri, S.; Kassiou, M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem., 2006, 13, 1991-2001.
66. Papadopoulos, V.; Lecanu, L. Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma. Exp. Neurol., 2009, 217, 53-57.
67. Rone, M. B.; Fan, J.; Papadopoulos, V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta, 2009, 1791, 646-658.
68. Rupprecht, R.; Papadopoulos, V.; Rammes, G.; Baghai, T. C.; Fan, J., Akula, N.; Groyer, G.; Adams, D.; Schumacher, M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov., 2010, 9, 971-988.
69. Papadopoulos, V.; Liu, J.; Culty, M. Is there a mitochondrial signaling complex facilitating cholesterol import? Mol. Cell Endocrinol., 2007, 265-266, 59-64.
70. Besman, M. J.; Yanagibashi, K.; Lee, T. D.; Kawamura, M.; Hall, P. F.; Shively, J. E. Identification of des-(Gly-Ile)-endozepine as an effector of corticotropin-dependent adrenal steroidogenesis: stimulation of cholesterol delivery is mediated by the peripheral benzodiazepine receptor. Proc. Natl. Acad. Sci. USA, 1989, 86, 4897-4901.
71. Stoffel-Wagner, B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol., 2001, 145, 669-679.
72. Delavoie, F.; Li, H.; Hardwick, M.; Robert, J. C.; Giatzakis, C.; Peranzi, G.; Yao, Z. X.; Maccario, J.; Lacapere, J. J.; Papadopoulos, V. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry, 2003, 42, 4506-4519.
73. Zheng, P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog. Neurobiol., 2009, 89, 134-152.
74. Lambert, J. J.; Cooper, M. A.; Simmons, R. D.; Weir, C. J.; Belelli, D. Neurosteroids: endogenous allosteric modulators of GABA(A) receptors. Psychoneuroendocrinol 2009, 34 (Suppl 1), S48-S58.
75. Melcangi, R. C.; Celotti, F.; Martini, L. Progesterone 5-alphareduction in neuronal and in different types of glial cell cultures: type 1 and 2 astrocytes and oligodendrocytes. Brain Res., 1994, 639, 202-206.
76. Melcangi, R. C.; Poletti, A.; Cavarretta, I.; Celotti, F.; Colciago, A.; Magnaghi, V.; Motta, M.; Negri-Cesi, P.; Martini, L. The 5alpha-reductase in the central nervous system: expression and modes of control. J. Steroid. Biochem. Mol. Biol., 1998, 65, 295-299.
77. Tsuruo, Y. Topography and function of androgen-metabolizing enzymes in the central nervous system. Anat. Sci. Int., 2005, 80, 1-11.
78. Belelli D.; Lambert, J. J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci., 2005, 6, 565-575.
79. Belelli, D.; Herd, M. B.; Mitchell, E. A.; Peden, D. R.; Vardy, A. W.; Gentet, L.; Lambert, J. J. Neuroactive steroids and inhibitory neurotransmission: mechanisms of action and physiological relevance. Neuroscience, 2006, 138, 821-829.
80. Maitra, R.; Reynolds, J. N. Modulation of GABA(A) receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABA(A) receptor isoforms. Can. J. Physiol. Pharmacol., 1998, 76, 909-920.
81. 11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2304-2319.
82. Nguyen, N.; Fakra, E.; Pradel, V.; Jouve, E.; Alquier, C.; Guern Le, M.; Micallef, J.; Blin, O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Human Psychopharmacol., 2006, 21, 139-149.
83. Schlichter, R.; Rybalchenko, V.; Poisbeau, P.; Verleye, M.; Gillardin, J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology, 2000, 39, 1523-1535.
84. Verleye, M.; Akwa, Y.; Liere, P.; Ladurelle, N.; Pianos, A.; Eychenne, B.; Schumacher, M.; Gillardin, J. M. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav., 2005, 82, 712-720.
85. Kita, A.; Kinoshita, T.; Kohayakawa, H.; Furukawa, K.; Akaike, A. Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216, a selective TSPO ligand. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 1040-1045.
86. Rupprecht, R.; Rammes, G.; Eser, D.; Baghai, T. C.; Schule, C.; Nothdurfter, C.; Troxler, T.; Gentsch, C.; Kalkman, H. O.; Chaperon, F.; Uzunov, V.; McAllister, K. H.; Bertaina-Anglade, V.; La Rochelle, C. D.; Tuerck, D.; Floesser, A.; Kiese, B.; Schumacher, M.; Landgraf, R.; Holsboer, F.; Kucher, K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science, 2009, 325, 490-493.
87. Chisari, M.; Eisenman, L. N.; Covey, D. F.; Mennerick, S.; Zorumski, C. F. The sticky issue of neurosteroids and GABA(A) receptors. Trends Neurosci., 2010, 33, 299-306.
88. Nohria, V.; Giller E. Ganaxolone. Neurotherapeutics, 2007, 102-105.
89. Beekman, M.; Ungard, J. T.; Gasior, M.; Carter, R. B.; Dijkstra, D.; Goldberg, S. R.; Witkin, J. M. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J. Pharmacol. Exp. Ther., 1998, 284, 868-877.
90. Luszczki, J. J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep., 2009, 61, 197-216.
91. A receptor function. Trends Pharmacol. Sci., 1995, 16, 295-303.
92. Britton, K. T.; Page, M.; Baldwin, H.; Koob, G. F. Anxiolytic activity of steroid anesthetic alphaxalone. J. Pharmacol. Exp. Ther., 1991, 258, 124-129.
93. Sigel, E. Mapping of the benzodiazepine recognition site on GABA(A) receptors. Curr. Top. Med. Chem., 2002, 2, 833-839.
94. McKernan, R. M.; Rosahl, T. W.; Reynolds, D. S.; Sur, C.; Wafford, K. A.; Atack, J. R.; Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett, L.; Bristow, L.; Marshall, G.; Macaulay, A.; Brown, N.; Howell, O.; Moore, K. W.; Carling, R. W.; Street, L. J.; Castro, J. L.; Ragan, C. I.; Dawson, G. R.; Whiting, P. J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat. Neurosci., 2000, 3, 587-592.
95. A receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci., 2005, 25, 10682-10688.
96. A receptor. J. Neurosci., 2002, 22, 5572-5580.
97. Benke, D.; Fritschy, J. M.; Trzeciak, A.; Bannwarth, W.; Mohler, H. Distribution, prevalence, and drug binding profile of gammaaminobutyric acid type A receptor subtypes differing in the betasubunit variant. J. Biol. Chem., 1994, 269, 27100-27107.
98. A-receptor subtypes really occur in the brain? Trends Neurosci., 1996, 19, 139-143.
99. A receptors of thalamocortical neurons: a molecular target for hypnotics. J. Neurosci., 2005, 25, 11513-11520.
100. Brickley, S. G.; Revilla, V.; Cull-Candy, S. G.; Wisden, W.; Farrant, M. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Nature, 2001, 2001/05/09, 88-92.
101. A receptor-mediated conductance in mouse neocortex. Cereb. Cortex., 2006, 16, 1134-1141.
102. A receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci., 1998, 18, 1693-1703.
103. Brown, N.; Kerby, J.; Bonnert, T. P.; Whiting, P. J.; Wafford, K. A. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br. J. Pharmacol., 2002, 136, 965-974.
104. Wohlfarth, K. M.; Bianchi, M. T.; Macdonald, R. L. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J. Neurosci., 2002, 22, 1541-1549.
105. A receptors: molecular determinants and significance in health and disease. Neurochem. Int., 2008, 52, 588-595.
106. Belelli, D.; Casula, A.; Ling, A.; Lambert, J. J. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology, 2002, 43, 651-661.
107. A receptors through two discrete transmembrane sites. Nature, 2006, 444, 486-489.
108. Anholt, R. R.; Pedersen, P. L.; De Souza, E. B.; Snyder, S. H. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem., 1986, 261, 576-583.
109. Joseph-Liauzun, E.; Delmas, P.; Shire, D.; Ferrara, P. Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure. J. Biol. Chem., 1998, 273, 2146-2152.
110. Charney, D. S.; Deutch, A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol., 1996, 10, 419-446.
111. Brandao, M. L.; Troncoso, A. C.; de Souza Silva, M. A.; Huston, J. P. The relevance of neuronal substrates of defense in the midbrain tectum to anxiety and stress: empirical and conceptual considerations. Eur. J. Pharmacol., 2003, 463, 225-233.
112. Bonin, R. P.; Orser, B. A. GABA(A) receptor subtypes underlying general anesthesia. Pharmacol. Biochem. Behav., 2008, 90, 105-112.
113. Di Chiara, G.; Acquas, E.; Tanda, G.; Cadoni, C. Drugs of abuse: biochemical surrogates of specific aspects of natural reward? Biochem. Soc. Symp., 1993, 59, 65-81.
114. Lingford-Hughes, A. R.; Davies, S. J.; McIver, S.; Williams, T. M.; Daglish, M. R.; Nutt, D. J. Addiction. Br. Med. Bull., 2003, 65, 209-222.
115. A receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr. Opin. Pharmacol., 2005, 5, 47-52.
116. Savic, M. M.; Obradovic, D. I.; Ugresic, N. D.; Bokonjic, D. R. Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes. Neural. Plast, 2005, 12, 289-298.
117. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci., 1992, 12, 1040-1062.